Enzo Biochem Price to Book Ratio 2010-2022 | ENZ
Historical price to book ratio values for Enzo Biochem (ENZ) over the last 10 years. The current price to book ratio for Enzo Biochem as of January 25, 2023 is 1.61.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Enzo Biochem Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-01-26 |
1.50 |
|
1.62 |
| 2022-10-31 |
2.14 |
$0.92 |
2.32 |
| 2022-07-31 |
2.37 |
$1.12 |
2.12 |
| 2022-04-30 |
2.55 |
$1.28 |
2.00 |
| 2022-01-31 |
3.22 |
$1.34 |
2.40 |
| 2021-10-31 |
3.44 |
$1.38 |
2.50 |
| 2021-07-31 |
3.26 |
$1.42 |
2.30 |
| 2021-04-30 |
3.07 |
$1.34 |
2.29 |
| 2021-01-31 |
2.82 |
$1.28 |
2.20 |
| 2020-10-31 |
1.82 |
$1.23 |
1.48 |
| 2020-07-31 |
2.38 |
$1.22 |
1.95 |
| 2020-04-30 |
3.02 |
$1.30 |
2.32 |
| 2020-01-31 |
2.51 |
$1.49 |
1.68 |
| 2019-10-31 |
3.16 |
$1.65 |
1.92 |
| 2019-07-31 |
3.91 |
$1.81 |
2.16 |
| 2019-04-30 |
3.47 |
$1.91 |
1.81 |
| 2019-01-31 |
3.76 |
$1.43 |
2.63 |
| 2018-10-31 |
3.32 |
$1.60 |
2.07 |
| 2018-07-31 |
4.42 |
$1.72 |
2.57 |
| 2018-04-30 |
6.00 |
$1.83 |
3.28 |
| 2018-01-31 |
7.36 |
$1.87 |
3.93 |
| 2017-10-31 |
9.85 |
$1.90 |
5.18 |
| 2017-07-31 |
10.85 |
$1.91 |
5.68 |
| 2017-04-30 |
8.80 |
$1.91 |
4.61 |
| 2017-01-31 |
6.68 |
$1.90 |
3.52 |
| 2016-10-31 |
6.10 |
$1.91 |
3.19 |
| 2016-07-31 |
6.97 |
$1.94 |
3.60 |
| 2016-04-30 |
4.98 |
$1.15 |
4.35 |
| 2016-01-31 |
4.74 |
$1.18 |
4.01 |
| 2015-10-31 |
3.72 |
$1.02 |
3.63 |
| 2015-07-31 |
3.00 |
$0.93 |
3.24 |
| 2015-04-30 |
2.80 |
$0.74 |
3.79 |
| 2015-01-31 |
3.15 |
$0.77 |
4.10 |
| 2014-10-31 |
5.22 |
$0.81 |
6.47 |
| 2014-07-31 |
4.80 |
$0.84 |
5.75 |
| 2014-04-30 |
4.20 |
$0.87 |
4.85 |
| 2014-01-31 |
2.81 |
$0.76 |
3.69 |
| 2013-10-31 |
2.49 |
$0.80 |
3.11 |
| 2013-07-31 |
2.18 |
$0.84 |
2.59 |
| 2013-04-30 |
2.24 |
$0.89 |
2.51 |
| 2013-01-31 |
2.89 |
$1.02 |
2.82 |
| 2012-10-31 |
2.00 |
$1.16 |
1.72 |
| 2012-07-31 |
1.50 |
$1.25 |
1.20 |
| 2012-04-30 |
2.74 |
$1.96 |
1.40 |
| 2012-01-31 |
2.55 |
$2.04 |
1.25 |
| 2011-10-31 |
2.86 |
$2.16 |
1.32 |
| 2011-07-31 |
3.84 |
$2.30 |
1.67 |
| 2011-04-30 |
3.99 |
$2.38 |
1.68 |
| 2011-01-31 |
4.96 |
$2.40 |
2.07 |
| 2010-10-31 |
4.31 |
$2.54 |
1.70 |
| 2010-07-31 |
4.60 |
$2.54 |
1.81 |
| 2010-04-30 |
5.97 |
$2.67 |
2.23 |
| 2010-01-31 |
4.74 |
$2.78 |
1.71 |
| 2009-10-31 |
5.51 |
$3.07 |
1.80 |
| 2009-07-31 |
5.10 |
$3.09 |
1.65 |
| 2009-04-30 |
4.10 |
$3.19 |
1.29 |
| 2009-01-31 |
4.89 |
$3.29 |
1.49 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.073B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
